Zydus Lifesciences has received final approval from the US Food and Drug Administration (USFDA) to market Amantadine extended-release capsules (68.5 mg) and tentative approval for 137 mg, intended for treating dyskinesia in Parkinson's disease patients. This approval allows Zydus to enjoy 180 days of exclusivity for the 68.5 mg version, produced at their facility in Ahmedabad SEZ - II, bringing the company's total USFDA approvals to 400. Following the announcement, Zydus shares surged 3.8%, reflecting strong investor confidence. In its recent financial report, Zydus reported a 31% increase in consolidated net profit for Q1 FY25, reaching Rs 1,420 crore, with significant growth in both domestic and US sales. The stock has seen a remarkable increase of 78.4% over the past year. Zydus Lifesciences continues to strengthen its position in the pharmaceutical market with a total market capitalization of Rs 1.13 trillion.